Korean J Intern Med > Volume 32(5); 2017 > Article
Lee: Significance of duodenal mucosal lesions: can they be a clue to a systemic disease?
See Article on Page 827-835
Upper gastrointestinal endoscopy is widely used in Korea not only for hospitalized patients but also for check-ups of healthy individuals. Endoscopically, duodenitis is defined as inflammation of the duodenal mucosa. The endoscopic terms for duodenopathy are erosive, hemorrhagic, and hyperemic changes, according to the Minimal Standard Terminology of the World Endoscopy Organization [1]. Although endoscopists frequently encounter duodenal ulcers and duodenitis, the duodenum is frequently overlooked during endoscopy because duodenal malignancy is rare [2]. The most common causes of duodenal ulcers are Helicobacter pylori and nonsteroidal anti-inflammatory drugs (NSAIDs) [3]; therefore, an examiner might assume any duodenal mucosal lesions identified to be one of these two etiologies. According to the 2015 Kyoto consensus report, duodenitis has various causes [4]. The proposed etiologies of duodenitis are H. pylori, other bacteria (mycobacteria and Tropheryma whipplei), fungi, parasites, viruses, external causes (e.g., alcohol, radiation, and drugs), allergic reactions, eosinophilic disease, and other diseases (e.g., Crohn’s disease, sarcoidosis, vasculitis, Henoch-Schonlein purpura, and celiac disease). Thus, the etiology of duodenitis is more complex than previously believed.
In the current issue of the Korean Journal of Internal Medicine, Han et al. [5] report a retrospective study of the characteristics of duodenitis and duodenal ulcers relating to primary and secondary duodenal lesions. They enrolled 475 patients hospitalized in a single institution due to duodenal mucosal lesions from 2011 to 2014. The authors categorized the primary and secondary causes of duodenal lesions according to underlying disease. The prevalence of H. pylori did not differ between the primary and secondary duodenal lesion groups; however, the number of users of NSAIDs or aspirin was significantly higher in the primary duodenal lesion group. Primary duodenal lesions were found in 454 patients (95.6%), and secondary duodenal lesions were found in 21 patients (4.4%). The most frequent secondary cause was inflammatory bowel disease (IBD). Other diseases were cytomegalovirus, Behcet’s disease, Henoch-Shonlein purpura, radiation-induced duodenitis, candida, tuberculosis enteritis, eosinophilic enteritis, and parasitic infection. Han et al. [5] reported that age and the extent of duodenal lesions were significant predictors of secondary duodenal lesions.
Kim et al. [6] reported that the prevalence of H. pylori in duodenal ulcers in the Korean population is 65.4%. Histologic duodenitis is associated with H. pylori in 75% to 82% of patients [7,8]. The duodenal bulb is the most common location of duodenal ulcers. In H. pylori-infected patients, a high gastric-acid output increases acid loading to the duodenum and results in gastric metaplasia in the duodenal bulb. Metaplastic epithelium can be infected with H. pylori, resulting in duodenitis, erosions, and ulcers. [3] Non-H. pylori and non-NSAID duodenal ulcers are reportedly associated with multiple ulcers; in contrast, H. pylori-related ulcers usually occur singly [9]. This result is similar to the finding of Han et al. [5].
NSAIDs are also important causes of gastroduodenal lesions. The prevalence of H. pylori-negative but NSAID-positive duodenal ulcers varies from 8.5% to 70% [10]. In Korea, the prevalence of duodenal and gastric ulcers is reportedly 12.3% and 23.6%, respectively, in patients taking NSAIDs. [6] Based on this study, duodenal ulcers are affected more markedly by H. pylori than by NSAIDs. The exact pattern of duodenal involvement of NSAID users is unknown. Because NSAIDs can influence the upper to lower gastrointestinal tract, instead of being confined to the bulb their effect may extend to the distal duodenum. In the study by Han et al. [5], although the primary duodenal lesion group contained a greater number of patients taking NSAIDs, the extent of duodenal mucosal lesions was greater in the secondary group. In previous studies, NSAIDs were found to affect the duodenal mucosa in only 13% of patients with H. pylori-negative duodenal ulcers [11], and histologic changes in the duodenum were negligible [12]. These results may explain the findings of Han et al. [5].
The duodenum is involved in 23% to 53% of IBD cases [13,14]; these are predominantly Crohn’s disease, which can involve the entire gastrointestinal system. Histologic duodenitis was diagnosed in 28.2% and 2.7% of Crohn’s disease and ulcerative colitis patients, respectively, and the prevalence of upper gastrointestinal tract involvement was higher in patients less than 18 years of age [15]. Han et al. [5] also reported that patients less than 30 years of age have predictive factors of secondary mucosal lesions due to systemic disease. The most common endoscopic findings of Crohn’s disease are erythema, edema, ulcers, and erosion. Granuloma is the definitive histopathologic finding of upper gastrointestinal Crohn’s disease, although its prevalence is low [16].
The indications for duodenal biopsy are evaluation of malabsorption, iron-deficiency anemia, gluten-sensitive enteropathy, neoplasia, and diarrhea, together with confirmation of ulceration induced by NSAIDs and bleeding from an unknown site [17]. Although identification of duodenal lesions by histopathologic findings is important, these are not strongly correlated with endoscopic findings [12,18]. Moreover, celiac disease is rare in Korea, unlike in Western countries, and duodenal biopsy for endoscopic duodenitis is reserved for cases with clinical suspicion of selected diseases.
This study is limited by its retrospective nature and the small number of patients with secondary duodenal lesions. Thus, the results could be biased if a particular disease predominated in patients with secondary duodenal lesions. Another limitation is that pathologic diagnosis was not performed in all cases, which might have introduced selection bias. Despite these limitations, this work is noteworthy because few studies have reported the extent of duodenal mucosal lesions. Endoscopists should consider causes other than H. pylori infection and NSAID use, and obtain biopsies in young patients with duodenitis beyond the second portion. Further large-scale studies should investigate the pattern of duodenal involvement in duodenitis of various etiologies.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. World Endoscopy Organization WEO (formerly known as OMED) committee for standardization and terminology; Aabakken L, et al.; Rembacken B. Minimal standard terminology for gastrointestinal endoscopy MST 3.0 [Internet]. Munich (DE): World Endoscopy Organization, c2005. [cited 2017 Aug 21]. Available from: http://www.worldendo.org/wp-content/uploads/2016/08/160803_MST30.pdf.

2. Goldner B, Stabile BE. Duodenal adenocarcinoma: why the extreme rarity of duodenal bulb primary tumors? Am Surg 2014. 80:956–959.
crossref pmid
3. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 10th ed. Philadelphia (PA): Saunders/Elsevier, 2016.

4. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353–1367.
crossref pmid pmc
5. Han Y, Jung HK, Chang JY, et al. Identification of distinctive clinical significance in hospitalized patients with endoscopic duodenal mucosal lesions. Korean J Intern Med 2017;32:827–835.
crossref pmid pmc pdf
6. Kim JI, Kim SG, Kim N, et al. Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol 2009;21:787–793.
crossref pmid
7. Caselli M, Gaudio M, Chiamenti CM, et al. Histologic findings and Helicobacter pylori in duodenal biopsies. J Clin Gastroenterol 1998;26:74–80.
crossref pmid
8. Mirbagheri SA, Khajavirad N, Rakhshani N, Ostovaneh MR, Hoseini SM, Hoseini V. Impact of Helicobacter pylori infection and microscopic duodenal histopathological changes on clinical symptoms of patients with functional dyspepsia. Dig Dis Sci 2012;57:967–972.
crossref pmid
9. Xia HH, Phung N, Kalantar JS, Talley NJ. Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease. Med J Aust 2000;173:515–519.
crossref pmid
10. Cekin AH, Taskoparan M, Duman A, et al. The role of Helicobacter pylori and NSAIDs in the pathogenesis of uncomplicated duodenal ulcer. Gastroenterol Res Pract 2012;2012:189373.
crossref pmid pmc pdf
11. Chu KM, Kwok KF, Law S, Wong KH. Patients with Helicobacter pylori positive and negative duodenal ulcers have distinct clinical characteristics. World J Gastroenterol 2005;11:3518–3522.
crossref pmid pmc
12. Lewis S, Stableforth W, Awasthi R, et al. An examination of the relationship between the endoscopic appearance of duodenitis and the histological findings in patients with epigastric pain. Int J Clin Exp Pathol 2012;5:581–587.
pmid pmc
13. Hori K, Ikeuchi H, Nakano H, et al. Gastroduodenitis associated with ulcerative colitis. J Gastroenterol 2008;43:193–201.
crossref pmid
14. Schmitz-Moormann P, Malchow H, Pittner PM. Endoscopic and bioptic study of the upper gastrointestinal tract in Crohn’s disease patients. Pathol Res Pract 1985;179:377–387.
crossref pmid
15. Sonnenberg A, Melton S, Genta R. Frequent occurrence of gastritis and duodenitis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:39–44.
crossref pmid
16. Diaz L, Hernandez-Oquet RE, Deshpande AR, Moshiree B. Upper gastrointestinal involvement in Crohn disease: histopathologic and endoscopic findings. South Med J 2015;108:695–700.
crossref pmid
17. Serra S, Jani PA. An approach to duodenal biopsies. J Clin Pathol 2006;59:1133–1150.
crossref pmid pmc
18. Sahin A, Cihangiroglu G, Bilgic Y, Calhan T, Cengiz M. Is duodenal biopsy appropriate in areas endemic for Helicobacter pylori? North Clin Istanb 2017;4:13–21.
pmid pmc

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6792    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2024 by Korean Association of Internal Medicine.

Close layer
prev next